CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors
CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in solid tumors, today announced the publication of a new manuscript in Molecular Therapy Oncology. The paper details compelling results from a comprehensive preclinical study evaluating CorriXR’s CRISPR-directed gene editing technology for the treatment of squamous cell lung carcinoma (LUSC), one of the most difficult-to-treat forms of non-small cell lung cancer (NSCLC). The study was conducted in collaboration with scientists at ChristianaCare’s Gene Editing Institute (GEI), a longstanding leader in translational gene editing research.
According to CorriXR, the findings add significant momentum to the company’s efforts to restore treatment sensitivity in tumors that have become resistant to standard therapies. “This foundational work strengthens CorriXR’s strategy of disrupting cancer cell survival pathways to restore sensitivity to standard therapies,” said Eric B. Kmiec, Ph.D., Founder and Chief Executive Officer of CorriXR Therapeutics and Executive Director of the Gene Editing Institute.
“These findings build on more than a decade of GEI research into NRF2, a master regulator of cellular stress responses and a well-documented driver of treatment resistance. We are encouraged by the consistency of results across in vitro human lung cancer models and our in vivo studies, and are actively pursuing IND-enabling work to bring this promising approach to patients.”
Study Overview and Rationale
Drug resistance is one of the most significant obstacles in the treatment of solid tumors. In cancers such as LUSC, patients often demonstrate initial responses to chemotherapy but quickly develop resistance, severely limiting therapeutic options. One of the most studied molecular drivers of this resistance is NRF2, a transcription factor responsible for regulating antioxidant pathways within the cell. Although its normal function is to protect healthy cells from oxidative stress, tumor cells can exploit NRF2 overactivation to shield themselves from chemotherapy and other treatments.
CorriXR’s approach leverages precision CRISPR gene editing to selectively disrupt NRF2 activity within tumor cells. By targeting and editing a subset of cancer cells, the company aims to collapse the tumor’s protective signaling network, thereby restoring chemosensitivity and enabling conventional therapies to work more effectively. The newly published preclinical data represent the most extensive evaluation to date of this mechanism in LUSC models.
Key Findings From the Published Study
The study revealed several important outcomes that support the advancement of CorriXR’s CRISPR-based therapeutic strategy into clinical development.
1. Restoration of Chemosensitivity
One of the most notable findings was that editing just 20–40% of LUSC cells to disrupt NRF2 was sufficient to significantly resensitize tumors to chemotherapy. The restored chemosensitivity produced meaningful reductions in tumor growth across both in vitro and in vivo models, underscoring the therapeutic power of targeting a critical resistance pathway rather than attempting to edit the entire tumor mass.
This outcome reflects a central pillar of CorriXR’s therapeutic philosophy: that strategic partial editing can trigger broader biological changes within the tumor microenvironment, effectively re-establishing vulnerability to drugs that previously failed.
2. Effective Disruption of NRF2-Driven Signaling
Tumors treated with CorriXR’s CRISPR-based therapy demonstrated:
- Reduced NRF2 expression
- Downregulation of NRF2-regulated downstream markers
- Impairment of tumor cell stress-response pathways
Together, these results indicate that the CRISPR strategy effectively interrupts the cancer’s resistance circuitry.
3. High Specificity and Minimal Off-Target Editing
Safety is a critical consideration in gene editing, and the study demonstrated a strong specificity profile. Off-target edits remained below 0.2%, which the authors noted is “below background” and within acceptable limits for translational gene editing therapies. These results suggest that the approach may be suitable for further regulatory evaluation.
4. Robust Delivery Achieved Via Lipid Nanoparticles (LNPs)
To translate CRISPR editing into a clinically viable therapy, efficient and tumor-targeted delivery is essential. The study utilized a lipid nanoparticle (LNP) delivery system, which achieved strong editing performance in:
- Engineered LUSC tumor models
- Patient-derived tumor models
This delivery success significantly strengthens the translational potential of the platform and reinforces the feasibility of advancing toward human studies.
Expert Insights: Addressing an Urgent Need in Oncology
“Treatment resistance remains one of the greatest challenges in oncology, and these data demonstrate that targeting NRF2 can meaningfully resensitize tumors with minimal off-target effects,” said Kelly Banas, Ph.D., lead author of the study and Associate Director of Research at the GEI. “This approach has the potential to lower chemotherapy doses, reduce toxicity, and help patients remain healthier throughout treatment.”
Dr. Kmiec emphasized the clinical relevance of the approach, noting that the strategy is designed to enhance existing therapies rather than replace them. “Instead of creating entirely new drugs, we are using gene editing to make existing ones effective again,” he said. “This is a powerful and pragmatic solution for patients who have exhausted current treatment options.”
Therapeutic Implications Beyond Lung Cancer
While the published research focused on LUSC, CorriXR and GEI note that NRF2-driven resistance appears across a wide range of solid tumor types. “NRF2 overactivation drives treatment resistance across multiple solid tumors, including head and neck squamous cell carcinoma (HNSCC),” Dr. Kmiec explained. “These data indicate that CRISPR-enabled targeting of NRF2 may disrupt the tumor microenvironment and address a shared mechanism of therapeutic failure.”
The company believes that its platform may have broad applicability in cancers such as:
- Head and neck squamous cell carcinoma (HNSCC)
- Esophageal cancer
- Liver cancer
- Additional tumors with known NRF2 pathway dysregulation
This expands the potential clinical reach of CorriXR’s technology and aligns with the company’s pipeline priorities.
Clinical Context: High Unmet Need in LUSC
LUSC represents 20–30% of all lung cancer cases, affecting an estimated 190,000 individuals annually in the United States. It is widely considered one of the more aggressive forms of NSCLC. Although chemotherapy remains a critical component of treatment, many patients develop resistance, leaving few effective alternatives.
Current attempts to overcome chemotherapy resistance often rely on dose escalation, which increases toxicity and diminishes quality of life. As a result, there is a pressing need for new therapeutic strategies that can restore sensitivity without subjecting patients to more damaging treatment regimens.
Because NRF2 is a validated driver of resistance across multiple cancers, targeting this pathway offers a rational and potentially transformative approach.
Next Steps: Advancing Toward IND and Clinical Development
The preclinical findings support CorriXR’s plan to accelerate development of its lead programs for both LUSC and HNSCC. The company and its collaborators are now:
- Independently validating results at commercial Contract Research Organizations (CROs)
- Conducting IND-enabling safety, toxicology, and regulatory studies
- Preparing documentation to support an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA)
- Exploring strategic partnerships to advance the therapeutic into clinical testing
These efforts position CorriXR to potentially initiate human trials following regulatory clearance.
Source Link: https://www.businesswire.com/
